PL1981904T3 - Domena peptydowa niezbędna do interakcji między otoczką wirusa należącego do grupy interferencyjnej HERV-W i receptorem hASCT - Google Patents

Domena peptydowa niezbędna do interakcji między otoczką wirusa należącego do grupy interferencyjnej HERV-W i receptorem hASCT

Info

Publication number
PL1981904T3
PL1981904T3 PL07730950T PL07730950T PL1981904T3 PL 1981904 T3 PL1981904 T3 PL 1981904T3 PL 07730950 T PL07730950 T PL 07730950T PL 07730950 T PL07730950 T PL 07730950T PL 1981904 T3 PL1981904 T3 PL 1981904T3
Authority
PL
Poland
Prior art keywords
herv
envelope
interaction
peptide domain
virus belonging
Prior art date
Application number
PL07730950T
Other languages
English (en)
Inventor
François Mallet
Guy Oriol
Valérie Cheynet
Original Assignee
Biomerieux S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux S.A. filed Critical Biomerieux S.A.
Publication of PL1981904T3 publication Critical patent/PL1981904T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/112Retroviridae (F), e.g. leukemia viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10061Methods of inactivation or attenuation
    • C12N2740/10063Methods of inactivation or attenuation by chemical treatment
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07730950T 2006-02-09 2007-02-09 Domena peptydowa niezbędna do interakcji między otoczką wirusa należącego do grupy interferencyjnej HERV-W i receptorem hASCT PL1981904T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0650468A FR2897062B1 (fr) 2006-02-09 2006-02-09 Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur asct

Publications (1)

Publication Number Publication Date
PL1981904T3 true PL1981904T3 (pl) 2017-09-29

Family

ID=37037521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07730950T PL1981904T3 (pl) 2006-02-09 2007-02-09 Domena peptydowa niezbędna do interakcji między otoczką wirusa należącego do grupy interferencyjnej HERV-W i receptorem hASCT

Country Status (15)

Country Link
US (2) US20090148454A1 (pl)
EP (1) EP1981904B9 (pl)
JP (2) JP2009525741A (pl)
CN (1) CN101379079B (pl)
AU (1) AU2007213591B2 (pl)
CA (1) CA2640793C (pl)
DK (1) DK1981904T3 (pl)
ES (1) ES2637961T3 (pl)
FR (1) FR2897062B1 (pl)
HU (1) HUE034297T2 (pl)
IL (1) IL193353A (pl)
NO (1) NO20083549L (pl)
PL (1) PL1981904T3 (pl)
PT (1) PT1981904T (pl)
WO (1) WO2007090967A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624994B2 (ja) * 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 新たなレセプター結合性リガンド、生物学的対象の細胞の検出におけるその使用
EP2387414A1 (en) 2009-01-13 2011-11-23 Transgene SA Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
CA3000884A1 (en) * 2015-10-05 2017-04-13 Metafora Biosystems Receptor-binding domains ligands for the detection, diagnosis and treatment of pancreatic cancer
JP7768775B2 (ja) * 2021-01-14 2025-11-12 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
EP4630804A1 (en) * 2022-12-06 2025-10-15 Metafora Biosystems Ligands specific for asct1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710075B1 (fr) * 1993-09-15 1995-10-27 Bio Merieux Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal.
FR2781802B1 (fr) 1998-07-31 2001-05-11 Bio Merieux Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Also Published As

Publication number Publication date
DK1981904T3 (en) 2017-07-10
WO2007090967A3 (fr) 2007-12-21
US10040829B2 (en) 2018-08-07
JP2016040295A (ja) 2016-03-24
JP2009525741A (ja) 2009-07-16
EP1981904A2 (fr) 2008-10-22
CN101379079B (zh) 2012-11-14
US20160090402A1 (en) 2016-03-31
FR2897062A1 (fr) 2007-08-10
WO2007090967A2 (fr) 2007-08-16
CN101379079A (zh) 2009-03-04
CA2640793C (fr) 2015-11-24
IL193353A (en) 2016-06-30
EP1981904B9 (fr) 2017-09-13
IL193353A0 (en) 2011-08-01
PT1981904T (pt) 2017-07-11
AU2007213591A1 (en) 2007-08-16
ES2637961T3 (es) 2017-10-18
EP1981904B1 (fr) 2017-04-05
JP6494487B2 (ja) 2019-04-03
AU2007213591B2 (en) 2011-10-06
FR2897062B1 (fr) 2011-11-04
CA2640793A1 (fr) 2007-08-16
NO20083549L (no) 2008-11-07
US20090148454A1 (en) 2009-06-11
HUE034297T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
IL239023A0 (en) Neutralizing antibodies to influenza viruses
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
DK2238142T3 (da) Makrocykliske indoler som hepatitis C-virusinhibitorer
EP2102238A4 (en) CD44 ANTIBODY
BRPI0716483A2 (pt) inibidores do vírus da hepatite c
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
EP2256030A4 (en) AIRCRAFT GROUP
FR2945538B1 (fr) Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
BRPI1011952A2 (pt) "composições de combustível compreendendo derivados de isopreno"
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
EP2211903A4 (en) CLL-1 ANTIBODY
BRPI0820407A2 (pt) Uso de anticorpos anti-cd40
EP2214711A4 (en) ANTI-RSV G PROTEIN ANTIBODY
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
EP2011869A4 (en) NEW ANTI-CD98 ANTIBODY
EP2306823A4 (en) 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
BRPI0912928A2 (pt) "composto, e, composição isenta de pirogênio"
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0821034A2 (pt) Vírus influenza modificado
EP2001400A4 (en) ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
BRPI0921044A2 (pt) composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina
EP2212431A4 (en) ANTIBODY AGAINST IREM-1
BRPI0907053A2 (pt) Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas